Patents by Inventor Istvan Enyedy
Istvan Enyedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220089592Abstract: This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I?), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.Type: ApplicationFiled: January 17, 2020Publication date: March 24, 2022Inventors: Brian T. Hopkins, Magnus Pfaffenbach, Tricia May-dracka, Ryan Evans, Fang Gao, Istvan Enyedy, Zhili Xin, Philippe Bolduc, Emily Anne Peterson
-
Publication number: 20220048884Abstract: Provided are compounds of Formula A or I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: ApplicationFiled: May 19, 2021Publication date: February 17, 2022Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin Shiang Lin, Brian Stuart Lucas, Bin Ma
-
Publication number: 20210340107Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: ApplicationFiled: April 2, 2021Publication date: November 4, 2021Inventors: Brian Stuart Lucas, Edward Yin Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
-
Patent number: 10968181Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: GrantFiled: December 27, 2017Date of Patent: April 6, 2021Assignee: BIOGEN MA INC.Inventors: Brian Stuart Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
-
Publication number: 20190389836Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.Type: ApplicationFiled: January 29, 2018Publication date: December 26, 2019Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin-Shiang Lin, Brian Stuart Lucas, Bin Ma
-
Publication number: 20190345112Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: ApplicationFiled: December 27, 2017Publication date: November 14, 2019Inventors: Brian Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
-
Patent number: 7960163Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: GrantFiled: February 29, 2008Date of Patent: June 14, 2011Assignee: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Publication number: 20080293696Abstract: A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.Type: ApplicationFiled: June 23, 2005Publication date: November 27, 2008Applicant: Bayer Pharmaceuticals CorporationInventors: Catherine Brennan, Julie A. Dixon, William J. Scott, Aniko Redman, Benjamin D. Jones, Barton Phillips, Philip Wickens, Istvan Enyedy, Ellalahewage Kumarasinghe, Charles Kreiman, Jacques Dumas, Uday Khire, Chih-Yuan Chuang, Harold C.E. Kluender, Zhenqiu Hong, Lei Wang, Donald Bierer
-
Publication number: 20080248566Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: ApplicationFiled: February 29, 2008Publication date: October 9, 2008Applicant: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Patent number: 7427689Abstract: A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(p-nitrophenyl)-2-propynoate.Type: GrantFiled: July 30, 2001Date of Patent: September 23, 2008Assignee: Georgetown UniversityInventors: Shaomeng Wang, Dajun Yang, Istvan Enyedy
-
Patent number: 7355015Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: GrantFiled: March 10, 2000Date of Patent: April 8, 2008Assignee: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Publication number: 20080058322Abstract: The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-XL. In particular, the present invention provides non-peptide cell permeable small molecules (e.g., tricyclo-dibenzo-diazocine-dioxides) that bind to a pocket in Bcl-2/Bcl-XL that block the anti-apoptotic function of these proteins in cancer cells and tumor tissues exhibiting Bcl-2 protein overexpression. In preferred embodiments, the small molecules of the present invention are active at the BH3 binding pocket of Bcl-2 family proteins (e.g., Bcl-2, Bcl-XL, and Mcl-1). The compositions and methods of the present invention are useful therapeutics for cancerous diseases either alone or in combination with chemotherapeutic or other drugs.Type: ApplicationFiled: June 8, 2007Publication date: March 6, 2008Applicant: The Regents of the University of MichiganInventors: Shaomeng Wang, Dajun Yang, Istvan Enyedy
-
Publication number: 20040023957Abstract: A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(posa-notrophenyl)-2-propynoate.Type: ApplicationFiled: August 4, 2003Publication date: February 5, 2004Inventors: Shaomeng Wang, Dajun Yang, Istvan Enyedy
-
Patent number: 6677377Abstract: The present invention relates to a method of inhibiting carcinoma progression wherein matriptase plays a role in a subject in need of such inhibition including administering to a subject an effective amount of a compound comprising two positively charged groups, which are the same or different. The groups are linked by a chemical group having a length of between 5 and 30 A, and preferably between 15 and 24 A. Diagnostic methods based on matriptase action and therapeutic methods involving inhibition of matriptase activity are provided.Type: GrantFiled: June 21, 2001Date of Patent: January 13, 2004Assignee: Georgetown University School of MedicineInventors: Chen-Yong Lin, Robert B. Dickson, Shaomeng Wang, Istvan Enyedy, Sheau-Ling Lee
-
Publication number: 20030092752Abstract: The present invention relates to a method of inhibiting carcinoma progression wherein matriptase plays a role in a subject in need of such inhibition including administering to a subject an effective amount of a compound comprising two positively charged groups, which are the same or different. The groups are linked by a chemical group having a length of between 5 and 30 A, and preferably between 15 and 24 A. Diagnostic methods based on matriptase action and therapeutic methods involving inhibition of matriptase activity are provided.Type: ApplicationFiled: June 21, 2001Publication date: May 15, 2003Inventors: Chen-Yong Lin, Robert B. Dickson, Shaomeng Wang, Istvan Enyedy, Sheau-Ling Lee